Xlife Sciences AG
SIX:XLS

Watchlist Manager
Xlife Sciences AG Logo
Xlife Sciences AG
SIX:XLS
Watchlist
Price: 20 CHF -0.5% Market Closed
Market Cap: 114.8m CHF
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

XLS Price Targets Summary
Xlife Sciences AG

There are no price targets for XLS.
XLS Lowest Forecast
Wall Street Target
Not Available
XLS Average Forecast
Wall Street Target
Not Available
XLS Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Xlife Sciences AG Competitors:
Price Targets
O
688238
Obio Technology Shanghai Corp Ltd
11% Upside
F
FLB
Fluidigm Corp
95% Upside
ERF
Eurofins Scientific SE
1% Downside
R
301333
R&G PharmaStudies Co Ltd
50% Upside
O
688238
Obio Technology Shanghai Corp Ltd
11% Upside
F
FLB
Fluidigm Corp
95% Upside
ERF
Eurofins Scientific SE
1% Downside
R
301333
R&G PharmaStudies Co Ltd
50% Upside
688222
HitGen Inc
11% Upside
I
INNOVACAP
Innova Captab Ltd
30% Upside
TARSONS
Tarsons Products Ltd
27% Upside
G
688046
GemPharmatech Co Ltd
54% Upside

Revenue
Forecast

Revenue Estimate
Xlife Sciences AG

For the last 4 years the compound annual growth rate for Xlife Sciences AG's revenue is 20%. The projected CAGR for the next 1 year is 157%.

20%
Past Growth
157%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Xlife Sciences AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
99%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Xlife Sciences AG

For the last 4 years the compound annual growth rate for Xlife Sciences AG's net income is 12%.

12%
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
XLS intrinsic value, competitors valuation, and company profile.
DCF Valuation
XLS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
XLS stock valuation using valuation multiples.
Wall Street Estimates
XLS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
XLS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XLS's stock price target?
Not Available

XLS doesn't have any price targets made by Wall Street professionals.

What is Xlife Sciences AG's Revenue forecast?
Projected CAGR
157%

For the last 4 years the compound annual growth rate for Xlife Sciences AG's revenue is 20%. The projected CAGR for the next 1 year is 157%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 264,000+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.